Given the enhanced responsiveness to PI3K inhibitors in breast cancer with multi‐PIK3CA mutations, we also explored the potential for similar responses in other cancer types, which could suggest broader applications for these inhibitors. This evidence concerns the gene PIK3CA and breast cancer.